We can’t show the full text here under this license.
SGLT2 inhibitors may prevent long-COVID memory and pain problems in people with type 2 diabetes
Updated
Abstract
Essence
Among adults with type 2 diabetes after COVID-19, SGLT2 inhibitor use was linked to lower recorded risk, including pain and cognitive symptoms.
Evidence
This retrospective TriNetX propensity-matched cohort compared 5,162 SGLT2 inhibitor users with 5,162 non-users diagnosed with COVID-19 from January 1, 2020, to June 30, 2024.
Caveat
Because exposure and outcomes came from observational records, the HR 0.85 association does not prove SGLT2 inhibitors prevent long COVID.
Simplified
Key numbers
0.85
Hazard Ratio for Risk
Compared to non-users in a matched cohort of 5,162 patients.
0.76
Hazard Ratio for Younger Patients
Among patients aged 18–64 years.
0.79
Hazard Ratio for Male Patients
Compared to non-SGLT2 inhibitor users.
Long Covid